Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 29 | 2026 | 427 | 7.110 |
Why?
|
| Tuberculosis | 30 | 2025 | 547 | 6.690 |
Why?
|
| Tuberculosis, Pulmonary | 19 | 2025 | 238 | 5.340 |
Why?
|
| HIV Infections | 25 | 2025 | 2046 | 3.980 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 8 | 2026 | 86 | 2.530 |
Why?
|
| Feces | 9 | 2025 | 718 | 2.410 |
Why?
|
| Antitubercular Agents | 11 | 2026 | 271 | 2.140 |
Why?
|
| Antibiotics, Antitubercular | 5 | 2025 | 38 | 2.060 |
Why?
|
| Rifampin | 8 | 2026 | 127 | 2.010 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2025 | 525 | 1.820 |
Why?
|
| Tuberculosis, Lymph Node | 4 | 2025 | 22 | 1.790 |
Why?
|
| Tuberculosis, Meningeal | 4 | 2025 | 31 | 1.780 |
Why?
|
| Sensitivity and Specificity | 17 | 2025 | 2076 | 1.690 |
Why?
|
| Anti-HIV Agents | 5 | 2025 | 348 | 1.590 |
Why?
|
| Sputum | 8 | 2025 | 114 | 1.510 |
Why?
|
| Interferon-gamma Release Tests | 4 | 2025 | 90 | 1.410 |
Why?
|
| DNA, Bacterial | 4 | 2024 | 479 | 1.040 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2025 | 397 | 0.950 |
Why?
|
| Adolescent | 32 | 2025 | 20803 | 0.940 |
Why?
|
| Isoniazid | 4 | 2022 | 68 | 0.920 |
Why?
|
| Killer Cells, Natural | 3 | 2019 | 351 | 0.870 |
Why?
|
| Masks | 1 | 2024 | 34 | 0.860 |
Why?
|
| Nucleic Acid Amplification Techniques | 4 | 2025 | 68 | 0.840 |
Why?
|
| Lipopolysaccharides | 5 | 2025 | 298 | 0.820 |
Why?
|
| Child | 34 | 2025 | 26172 | 0.800 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2021 | 15 | 0.690 |
Why?
|
| BCG Vaccine | 5 | 2023 | 105 | 0.670 |
Why?
|
| Molecular Typing | 1 | 2020 | 32 | 0.650 |
Why?
|
| Humans | 63 | 2026 | 130042 | 0.630 |
Why?
|
| Contact Tracing | 4 | 2022 | 60 | 0.620 |
Why?
|
| Influenza Vaccines | 2 | 2015 | 502 | 0.610 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 94 | 0.610 |
Why?
|
| HIV Seropositivity | 1 | 2020 | 125 | 0.610 |
Why?
|
| Mycobacterium bovis | 2 | 2022 | 29 | 0.600 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 230 | 0.580 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 231 | 0.570 |
Why?
|
| HIV | 2 | 2023 | 173 | 0.560 |
Why?
|
| Family | 1 | 2021 | 587 | 0.520 |
Why?
|
| Betacoronavirus | 1 | 2020 | 271 | 0.520 |
Why?
|
| Influenza A virus | 2 | 2016 | 142 | 0.510 |
Why?
|
| Medication Adherence | 1 | 2020 | 337 | 0.510 |
Why?
|
| Child, Preschool | 15 | 2025 | 15003 | 0.510 |
Why?
|
| Young Adult | 13 | 2025 | 9985 | 0.500 |
Why?
|
| HIV-1 | 1 | 2020 | 494 | 0.500 |
Why?
|
| Flow Cytometry | 2 | 2016 | 765 | 0.490 |
Why?
|
| Africa South of the Sahara | 3 | 2025 | 121 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 336 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 347 | 0.460 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 311 | 0.450 |
Why?
|
| Organ Transplantation | 1 | 2017 | 170 | 0.440 |
Why?
|
| Adult | 21 | 2025 | 31006 | 0.430 |
Why?
|
| Infant | 11 | 2025 | 13265 | 0.420 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 358 | 0.410 |
Why?
|
| Female | 23 | 2025 | 70230 | 0.400 |
Why?
|
| Pandemics | 1 | 2020 | 1110 | 0.390 |
Why?
|
| Pleural Effusion | 1 | 2014 | 103 | 0.390 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2026 | 890 | 0.390 |
Why?
|
| Male | 21 | 2025 | 64365 | 0.390 |
Why?
|
| Fever | 2 | 2021 | 310 | 0.380 |
Why?
|
| Drug Interactions | 2 | 2025 | 237 | 0.370 |
Why?
|
| Family Characteristics | 4 | 2021 | 93 | 0.370 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2024 | 163 | 0.360 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 309 | 0.350 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1707 | 0.350 |
Why?
|
| Vaccination | 3 | 2023 | 1051 | 0.350 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 460 | 0.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 501 | 0.340 |
Why?
|
| Risk Assessment | 1 | 2020 | 3676 | 0.340 |
Why?
|
| Mozambique | 3 | 2025 | 21 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2025 | 1262 | 0.320 |
Why?
|
| Tuberculosis, Renal | 1 | 2009 | 3 | 0.310 |
Why?
|
| Pregnancy | 4 | 2019 | 7388 | 0.300 |
Why?
|
| Tuberculosis, Miliary | 1 | 2009 | 10 | 0.300 |
Why?
|
| Bias | 4 | 2025 | 148 | 0.300 |
Why?
|
| Tanzania | 3 | 2024 | 68 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2567 | 0.290 |
Why?
|
| Pediatrics | 1 | 2018 | 1242 | 0.290 |
Why?
|
| Diarylquinolines | 2 | 2026 | 9 | 0.280 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 1171 | 0.280 |
Why?
|
| Influenza, Human | 1 | 2015 | 703 | 0.280 |
Why?
|
| Retrospective Studies | 8 | 2024 | 17536 | 0.280 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2026 | 848 | 0.270 |
Why?
|
| Prospective Studies | 5 | 2025 | 6392 | 0.270 |
Why?
|
| California | 2 | 2018 | 127 | 0.260 |
Why?
|
| Antigens, Bacterial | 2 | 2025 | 317 | 0.230 |
Why?
|
| Age Factors | 3 | 2025 | 2821 | 0.230 |
Why?
|
| Coinfection | 3 | 2025 | 186 | 0.220 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2026 | 155 | 0.220 |
Why?
|
| Mass Screening | 5 | 2022 | 817 | 0.210 |
Why?
|
| Vaccines, Inactivated | 2 | 2015 | 147 | 0.210 |
Why?
|
| Case-Control Studies | 2 | 2025 | 3350 | 0.200 |
Why?
|
| Infant, Newborn | 3 | 2025 | 8545 | 0.190 |
Why?
|
| Health Personnel | 2 | 2025 | 537 | 0.190 |
Why?
|
| DNA Methylation | 2 | 2020 | 1075 | 0.190 |
Why?
|
| Levonorgestrel | 1 | 2022 | 20 | 0.180 |
Why?
|
| Child Behavior | 2 | 2021 | 232 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 53 | 0.180 |
Why?
|
| Pharmacovigilance | 1 | 2021 | 12 | 0.180 |
Why?
|
| Oxazines | 1 | 2021 | 34 | 0.170 |
Why?
|
| Tuberculin Test | 2 | 2021 | 119 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 154 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 45 | 0.170 |
Why?
|
| Interferon-gamma | 3 | 2025 | 542 | 0.170 |
Why?
|
| Trichomonas Vaginitis | 1 | 2020 | 14 | 0.170 |
Why?
|
| Latent Tuberculosis | 1 | 2022 | 74 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2021 | 108 | 0.170 |
Why?
|
| Gastrointestinal Contents | 1 | 2020 | 12 | 0.160 |
Why?
|
| Gonorrhea | 1 | 2020 | 43 | 0.160 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 40 | 0.160 |
Why?
|
| Drug Monitoring | 2 | 2020 | 288 | 0.160 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 52 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 4035 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 47 | 0.160 |
Why?
|
| Pyridones | 1 | 2021 | 142 | 0.160 |
Why?
|
| Social Stigma | 1 | 2020 | 80 | 0.160 |
Why?
|
| Alanine | 1 | 2020 | 160 | 0.150 |
Why?
|
| Piperazines | 1 | 2021 | 269 | 0.150 |
Why?
|
| Self Efficacy | 1 | 2020 | 209 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 700 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1391 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3775 | 0.150 |
Why?
|
| Leukocytes | 1 | 2020 | 205 | 0.140 |
Why?
|
| Adolescent Behavior | 1 | 2020 | 167 | 0.140 |
Why?
|
| Sexual Behavior | 1 | 2020 | 232 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 71 | 0.140 |
Why?
|
| Chemokine CCL4 | 2 | 2016 | 13 | 0.140 |
Why?
|
| Radiography, Thoracic | 2 | 2021 | 145 | 0.140 |
Why?
|
| Ascaris lumbricoides | 1 | 2018 | 19 | 0.140 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 16 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2021 | 5034 | 0.140 |
Why?
|
| Caregivers | 2 | 2022 | 589 | 0.140 |
Why?
|
| Schistosomiasis | 1 | 2018 | 51 | 0.130 |
Why?
|
| Th1 Cells | 1 | 2018 | 158 | 0.130 |
Why?
|
| Ascariasis | 1 | 2018 | 76 | 0.130 |
Why?
|
| Middle Aged | 5 | 2025 | 28296 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2020 | 1481 | 0.130 |
Why?
|
| Public Health | 1 | 2019 | 268 | 0.130 |
Why?
|
| Antigens, CD | 2 | 2016 | 409 | 0.120 |
Why?
|
| Ethiopia | 2 | 2021 | 22 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2019 | 292 | 0.120 |
Why?
|
| Isotopes | 1 | 2016 | 24 | 0.120 |
Why?
|
| Biomarkers | 2 | 2016 | 3355 | 0.120 |
Why?
|
| Comorbidity | 1 | 2020 | 1583 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2021 | 1685 | 0.110 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2015 | 112 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2020 | 801 | 0.110 |
Why?
|
| Ionomycin | 1 | 2014 | 15 | 0.110 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2014 | 56 | 0.110 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2014 | 15 | 0.110 |
Why?
|
| Antigens, Surface | 1 | 2015 | 112 | 0.110 |
Why?
|
| Plasma Cells | 1 | 2015 | 54 | 0.110 |
Why?
|
| Risk Factors | 4 | 2025 | 10949 | 0.110 |
Why?
|
| Neutralization Tests | 1 | 2015 | 226 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 335 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2019 | 501 | 0.100 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2014 | 128 | 0.100 |
Why?
|
| Encephalitis, Viral | 1 | 2013 | 20 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2016 | 435 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 198 | 0.100 |
Why?
|
| Prevalence | 1 | 2020 | 2687 | 0.100 |
Why?
|
| Uganda | 2 | 2025 | 83 | 0.100 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 192 | 0.090 |
Why?
|
| United States | 3 | 2022 | 11891 | 0.090 |
Why?
|
| Postpartum Period | 1 | 2014 | 238 | 0.090 |
Why?
|
| Single-Cell Analysis | 1 | 2016 | 349 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 508 | 0.090 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 61 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2322 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 781 | 0.090 |
Why?
|
| Genotype | 1 | 2017 | 2587 | 0.090 |
Why?
|
| South Africa | 2 | 2021 | 98 | 0.080 |
Why?
|
| Registries | 1 | 2018 | 1606 | 0.080 |
Why?
|
| Reference Standards | 2 | 2022 | 231 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 289 | 0.080 |
Why?
|
| Cytokines | 1 | 2016 | 1331 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 977 | 0.080 |
Why?
|
| Pyrazinamide | 1 | 2009 | 10 | 0.080 |
Why?
|
| Adoption | 1 | 2009 | 18 | 0.070 |
Why?
|
| Global Health | 2 | 2025 | 622 | 0.070 |
Why?
|
| Seizures | 1 | 2013 | 874 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2020 | 4644 | 0.070 |
Why?
|
| Developing Countries | 1 | 2009 | 303 | 0.060 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2026 | 85 | 0.060 |
Why?
|
| Alaska | 1 | 2025 | 10 | 0.060 |
Why?
|
| Phenotype | 1 | 2016 | 4457 | 0.060 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2025 | 19 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2026 | 129 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 5167 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2025 | 227 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2023 | 1282 | 0.050 |
Why?
|
| Time Factors | 1 | 2014 | 6167 | 0.050 |
Why?
|
| Tuberculosis Vaccines | 1 | 2023 | 14 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 360 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2019 | 2883 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 630 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2025 | 358 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 131 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 61 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2023 | 229 | 0.050 |
Why?
|
| Mutation | 2 | 2026 | 6069 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 819 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2023 | 277 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2021 | 90 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 77 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2025 | 710 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2021 | 142 | 0.040 |
Why?
|
| Health Facilities | 1 | 2021 | 66 | 0.040 |
Why?
|
| Sex Factors | 1 | 2025 | 1340 | 0.040 |
Why?
|
| Goals | 1 | 2022 | 126 | 0.040 |
Why?
|
| Botswana | 1 | 2021 | 76 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2021 | 270 | 0.040 |
Why?
|
| Oxazoles | 1 | 2020 | 21 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2026 | 943 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 135 | 0.040 |
Why?
|
| Cough | 1 | 2021 | 97 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2020 | 49 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 349 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2019 | 60 | 0.040 |
Why?
|
| Weight Gain | 1 | 2021 | 384 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 293 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 65 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 86 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2018 | 71 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2018 | 144 | 0.030 |
Why?
|
| Incidence | 1 | 2025 | 3314 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1398 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2016 | 33 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 52 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 71 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2016 | 70 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 2289 | 0.030 |
Why?
|
| Schools | 1 | 2017 | 235 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 252 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 1209 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2461 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2018 | 2400 | 0.020 |
Why?
|
| Aged | 1 | 2022 | 20805 | 0.010 |
Why?
|
| Animals | 1 | 2018 | 33638 | 0.010 |
Why?
|